27 phd-in-architecture-landscape-built-environment PhD positions at University of Cambridge
Sort by
Refine Your Search
-
The PhD studentship will be based at the University of Cambridge in the Department of Materials Science and Metallurgy as part of the Structural Materials Group. The Structural Materials Group is a
-
Location: West Cambridge Funder: Tata Steel and the University of Cambridge Duration: 4 years from 1 October 2026 Supervisors: Prof Howard Stone and Dr David Collins Location: The PhD studentship
-
non-clinical PhD studentship in cardiometabolic research, commencing October 2026 in the Department of Medicine (VPD Heart & Lung Research Institute), University of Cambridge. The project will be based
-
This is a four-year (1+3 MRes/PhD) studentship funded through the Cambridge EPSRC Centre for Doctoral Training in Future Infrastructure and Built Environment: Unlocking Net Zero (FIBE3 CDT). Further
-
metabolomics, as well as imaging mass cytometry, and test the effect of AZ clinical compounds on the immune-metabolic landscape of our PanIN-to-PDAC models. Dr Koulman will provide training and support with
-
is characterizing the solid-state landscape of drug candidates, which can involve complex solid-phase transitions such as the dehydration of hydrates, desolvation of solvates, and solid-solid phase
-
OBJECTIVES � Primary focus areas, with potential to tailor according to your interests.� Assess how nesting environment and microbial supplementation influence microbiome colonisation.� Determine microbiome
-
PhD studentship: Defining the role of the pioneer factor FOXA1 in hormone-dependent cancer Supervisor: Professor Jason Carroll Course start date: 1st October 2026 Project details For further
-
We invite applications from creative and motivated individuals to join Professor Sir Shankar Balasubramanian's group for a 4-year PhD studentship, working on a multidisciplinary project exploiting
-
of the chromatin landscape in prostate cancer. Nat Commun. 2022 Apr 27;13(1):2282 https://pubmed.ncbi.nlm.nih.gov/35477723/ Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer